BSX Boston Scientific Corp

  1. Stocks
  2. Healthcare
  3. NYSE: BSX

Price (delayed)

$50.37

Market cap

$73B

P/E Ratio

20.23

Dividend/share

N/A

EPS

$2.49

Enterprise value

$85.08B

?
Relative Growth: Rel. Growth: 87
Relative Strength: Rel. Strength: 8
Relative Valuation: Rel. Valuation: 67
Relative Profitability: Rel. Profitability: 88

Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance ...

Highlights
The P/E is 69% below the 5-year quarterly average of 64.9 and 44% below the last 4 quarters average of 35.9
Boston Scientific's net income has increased by 47% YoY and by 3.1% QoQ
The equity has grown by 11% YoY but it has contracted by 3.6% from the previous quarter
BSX's quick ratio is down by 43% since the previous quarter and by 14% year-on-year
Boston Scientific's debt has increased by 14% QoQ and by 9% YoY
Sector: Healthcare
Industry: Medical Devices
Website: http://www.bostonscientific.com
Peers: EW SYK MMSI MDT

Key stats

What are the main financial stats of BSX

BSX stock price

How has the Boston Scientific stock price performed over time
Intraday
2.03%
1 week
-2.82%
1 month
16.62%
1 year
-52.12%
YTD
-47.17%
QTD
18.02%

Financial performance

How have Boston Scientific's revenue and profit performed over time
Revenue
$21B
Gross profit
$14.68B
Operating income
$4.15B
Net income
$3.68B
Gross margin
69.9%
Net margin
17.5%
Boston Scientific's net income has increased by 47% YoY and by 3.1% QoQ
Boston Scientific's operating income has increased by 32% YoY and by 9% from the previous quarter
Boston Scientific's net margin has increased by 30% YoY
BSX's operating margin is up by 16% year-on-year and by 8% since the previous quarter

Price vs fundamentals

How does BSX's price correlate with its fundamentals

Growth

What is Boston Scientific's growth rate over time

Valuation

What is Boston Scientific stock price valuation
BSX P/E details
P/E
20.23
P/B
3
P/S
3.53
EV/EBIT
20.11
EV/EBITDA
15.08
EV/Sales
4.05
The P/E is 69% below the 5-year quarterly average of 64.9 and 44% below the last 4 quarters average of 35.9
The EPS has increased by 46% YoY and by 3.3% from the previous quarter
The stock's price to book (P/B) is 35% less than its 5-year quarterly average of 4.6 and 33% less than its last 4 quarters average of 4.5
The equity has grown by 11% YoY but it has contracted by 3.6% from the previous quarter
BSX's P/S is 42% below its 5-year quarterly average of 6.1 and 36% below its last 4 quarters average of 5.5
The revenue has increased by 14% YoY

Efficiency

How efficient is Boston Scientific business performance
The return on assets has grown by 33% year-on-year
The return on equity has increased by 30% year-on-year
The ROS has increased by 12% YoY
BSX's ROIC is up by 12% YoY

Dividends

What is BSX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BSX.

Financial health

How did Boston Scientific financials performed over time
Boston Scientific's total assets is 126% more than its total liabilities
BSX's quick ratio is down by 43% since the previous quarter and by 14% year-on-year
BSX's current ratio is down by 35% since the previous quarter and by 9% year-on-year
Boston Scientific's debt is 49% lower than its equity
Boston Scientific's debt to equity has increased by 19% from the previous quarter
Boston Scientific's debt has increased by 14% QoQ and by 9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.